patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug

save

(bempedoic acid + ezetimibe)

Marketedupdated 2mo ago

by $ESPR Esperion Therapeutics, Inc.

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

indications

investigational

Hyperlipidemia

all catalysts(9)

approval · 9

view all 9 catalysts →

News(0)

no news has mentioned this drug yet

brand

Nexlizet

generic

(bempedoic acid + ezetimibe)

MOA

12.1 Mechanism of Action NEXLIZET contains bempedoic acid and ezetimibe. NEXLIZET reduces elevated LDL-C through inhibition of cholesterol synthesis in the liver and absorption in the intestine. Bempedoic acid Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors. Ezetimibe Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in LDL receptors, resulting in clearance of cholesterol from the blood.

indication

Heterozygous Familial Hypercholesterolemia (heFH)

phase

marketed

(bempedoic acid + ezetimibe)

indications

all catalysts(9)

News(0)

Report a data issue

comments(0)

Patent cliff

patents (8)

FDA exclusivities (2)

🐶 often sniffed alongside